Dr. Skoulidis on the Rationale to Target TROP2 in Lung Cancer

Video

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the rationale to target TROP-2 in lung cancer.

Ferdinandos Skoulidis, MD, PhD, MRCP, assistant professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the rationale to target TROP-2 in lung cancer.

TROP2 is a transmembrane glycoprotein that is involved in intracellular calcium signaling transduction and facets of tumorigenesis, including proliferation and metastasis, Skoulidis explains. Notably, TROP2 is overexpressed across a range of cancer types, including lung adenocarcinoma and squamous cell lung carcinoma, Skoulidis adds. As such, TROP2-directed treatments could offer a new generation of precision medicine–based lung cancer treatment.

Findings from the ongoing phase 1 TROPION-PanTumor01 trial (NCT03401385), which were presented during the 2021 ASCO Annual Meeting, demonstrated encouraging clinical efficacy with the TROP2-directed antibody-drug conjugate datopotamab deruxtecan (dato-DXd; DS-1062a) in patients with relapsed/refractory advanced or metastatic non–small cell lung cancer. At the dosing regimen of 6 mg/kg every 3 weeks, dato-DXd elicited an overall response rate of 26% and a median duration of response of 10.5 months in these patients, many of whom received prior immunotherapy and chemotherapy, Skoulidis concludes.

Related Videos
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Stephen V. Liu, MD
Debu Tripathy, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Millie Das, MD
Debu Tripathy, MD